echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nature sub-journal: Screening of clinical drug candidates through organoids derived from solid tumor cancer patients

    Nature sub-journal: Screening of clinical drug candidates through organoids derived from solid tumor cancer patients

    • Last Update: 2022-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In 2009, Hans Clevers et .


    In 2009, Hans Clevers et .


    In recent years, research results in the field of organoids have continued, and many new types of organoids and more complex organoids have emerged, bringing more powerful tools to the fields of new drug research and development, precision


    On April 25, 2022, researchers from CrownBio, Merus, and the Barcelona Institute of Science and Technology jointly published a paper entitled: Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR in Nature Cancer, a sub-journal of Nature × Research paper on LGR5 bispecific antibody with efficacy in epithelial tumo.


    For the first time, the study screened more than 500 bispecific antibodies using a library of organoids from cancer patients, and found an EGFR × LGR5 bispecific antibody named MCLA-158, which can effectively inhibit theGrowth of colorectal cancer organoids and prevention of metastas.


    In October 2021, Merus reported on the safety, tolerability and antitumor efficacy of a mid-stage clinical trial of its EGFR × LGR5 bispecific antibody named MCLA-158 in advanced head and neck squamous cell carcinoma (HNSCC) Active, 3 of 7 patients experienced a partial response, 1 of them achieved a complete response, and tumor shrinkage was observed in all 7 patien.


    In October 2021, Merus reported on the safety, tolerability and antitumor efficacy of a mid-stage clinical trial of its EGFR × LGR5 bispecific antibody named MCLA-158 in advanced head and neck squamous cell carcinoma (HNSCC) Active, 3 of 7 patients experienced a partial response, 1 of them achieved a complete response, and tumor shrinkage was observed in all 7 patien.


    MCLA-158 (Petosemtamab), a bispecific antibody that recognizes two proteins on the surface of cancer stem cells, EGFR and LGR5, EGFR promotes uncontrolled cell growth, while LGR5 is on the surface of cancer stem cells responsible for the spread of canc.


    MCLA-158 inhibits the EGFR protein in cancer stem cells with the LGR5 marker, thereby blocking the growth and survival of cancer stem cells that cause cancer to spre.


    MCLA-158 inhibits the EGFR protein in cancer stem cells with the LGR5 marker, thereby blocking the growth and survival of cancer stem cells that cause cancer to spre.


    Previous studies have shown that MCLA-158 inhibits production in preclinical tumor models of head and neck tumors, esophageal tumors, and gastric tumors, as well as inhibits the growth and metastasis of colorectal cancer organoi.


    To further develop and characterize this bispecific antibody, researchers at HUB Organoids (created by organoid pioneer Hans Clevers) established a large library of organoids, including organoids from colorectal cancer patients, from colorectal cancer metastases organoids to the liver as well as organoids from normal noncancerous tiss.


    In the early stages of drug development, using organoids from patient tumor tissue can help identify therapeutic drugs that are effective in patients, even in tumors harboring specific mutatio.


    In this study, the research team identified MCLA-158 from more than 500 bispecific antibodies in high-throughput screening of colorectal cancer patient-derived organoids and healthy colonic mucosa-derived organoi.


    MCLA-158 has demonstrated therapeutic properties in preclinical models of several epithelial cancer types, such as growth inhibition of KRAS-mutant colorectal cancer, blockade of metastasis initiation, and inhibition of tumor grow.


    MCLA-158 has demonstrated therapeutic properties in preclinical models of several epithelial cancer types, such as growth inhibition of KRAS-mutant colorectal cancer, blockade of metastasis initiation, and inhibition of tumor grow.


    Paper link:

    https:// Leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.